Models of Exacerbations in Asthma and COPD
Editor(s): Sjöbring, U. (Lund)Taylor, J.D. (Lund)
A Human Rhinovirus Model of Chronic Obstructive Pulmonary Disease ExacerbationsContoli M.a,b · Caramori G.a · Mallia P.b · Papi A.a · Johnston S.baDepartment of Clinical and Experimental Medicine, Research Center on Asthma and COPD, University of Ferrara, Ferrara, Italy; b Department of Respiratory Medicine, National Heart and Lung Institute and Wright Fleming Institute of Infection and Immunity, Imperial College London, London, UK
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: August 03, 2007
Cover Date: 2007
Number of Print Pages: 12
Number of Figures: 0
Number of Tables: 0
ISBN: 978-3-8055-8332-9 (Print)
eISBN: 978-3-8055-8173-8 (Online)
Abstract
Chronic obstructive pulmonary disease (COPD) exacerbations are common events that punctuate the natural history of COPD contributing to disease severity progression and being the major cause of COPD-related morbidity and mortality. Currently available pharmacological strategies are only partially effective at reducing or preventing COPD exacerbations. Viral infections are the most frequent cause of COPD exacerbations. The recent development of a human experimental model of rhinovirus-induced COPD exacerbations represents an innovative tool with the potential to increase our understanding of the inflammatory and immunological mechanisms that lead COPD patients to exacerbate after respiratory virus infections. Moreover this model will provide the opportunity to test, in a carefully controlled setting, novel pharmacological compounds with a potential for treating and preventing COPD exacerbations. In this chapter we will focus on the role of viral infections in COPD exacerbations and will discuss preliminary reports regarding the development of this human model of virus-induced COPD exacerbation.
Related Articles:
Article / Publication Details
Published online: August 03, 2007
Cover Date: 2007
Number of Print Pages: 12
Number of Figures: 0
Number of Tables: 0
ISBN: 978-3-8055-8332-9 (Print)
eISBN: 978-3-8055-8173-8 (Online)
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission